Tuberculosis is a global health problem, and chemotherapy is the most effective method for its control. A major issue during tuberculosis treatment is drug-induced liver injury 1 . Once liver injury occurs, the antituberculosis regimen must be altered or discontinued, which can result in relapse, drug resistance and tuberculosis-related death. Both RIF and INH are first-line antituberculosis drugs. The combination of these two drugs is highly effective. However, this combination frequently causes liver injury or even liver failure. Extensive studies have been conducted to investigate liver injury caused by RIF and INH in mice and rats [2] [3] [4] ; nevertheless, these studies poorly mimicked hepatotoxicity in humans. Species differences between rodents and humans in responding to RIF or INH are expected.
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PXR is a ligand-dependent transcription factor that regulates a gene network involved in the metabolism of xenobiotics and endobiotics 5 . The ability of chemicals to activate PXR is species dependent. RIF is a human PXR-specific activator that has a very weak effect on mouse Pxr 6 . To overcome the species differences in RIF-mediated PXR activation, we used PXR-humanized (hPXR) mice. After cotreatment with RIF and INH (Supplementary Fig. 1 ), we found higher amounts of serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activity in hPXR mice compared to in wildtype (WT) or Pxr-null mice (Fig. 1a-d) . In addition, we observed bile plugs in the liver of hPXR mice co-treated with RIF and INH ( Fig. 1e and Supplementary Fig. 2) , with an average of 2.38 plugs per view of liver sections at ×100 magnification. This phenotype was not present in WT (Fig. 1f) or Pxr-null (Fig. 1g) mice under the same treatment or in other hPXR treatment groups (Fig. 1h-j) .
These results indicate that human PXR is a key modulator of the hepatotoxicity produced by co-therapy with RIF and INH. Notably, these phenotypes mimic the hepatotoxicity in patients with tuberculosis under RIF and INH chemotherapy. In a clinical trial of RIF and INH co-therapy, bile pigments were observed in 17 of 28 subjects (60.7%) as revealed by liver biopsies, and the elevation of ALT activity in the subjects was in accordance with the degree of pathological changes 7 . We here show bile plugs in a mouse model and suggest that the hPXR mouse model is an appropriate model to study the liver injury produced by co-treatment with RIF and INH.
The risk of hepatotoxicity is considerably higher in patients receiving both RIF and INH than in those receiving either RIF or INH alone 8 . INH hepatotoxicity is thought to be dependent on metabolic activation by arylamine N-acetyltransferase and CYP2E1 (refs. 9,10) . RIF is a potent enzyme inducer in humans, so it was proposed that RIF potentiates INH hepatotoxicity through enzymatic induction and subsequent metabolic activation of INH 11 . However, RIF does not regulate the expression of arylamine N-acetyltransferase or CYP2E1 (refs. 12,13). Acetylhydrazine (AcHZ) and hydrazine are INH metabolites that were proposed to be responsible for INH-induced liver injury 14, 15 . Here we individually administered INH, AcHZ and hydrazine to hPXR mice together with RIF. We found liver injury only in the hPXR mice co-treated with RIF and INH ( Supplementary Fig. 3 ), suggesting that AcHZ and hydrazine do not cause INH-related hepatotoxicity. In a recent report, a reactive metabolite of INH was identified 16 . However, RIF pretreatment does not potentiate INH bioactivation ( Supplementary Fig. 4 ). Thus, a new mechanism that is independent of INH metabolism is expected for the liver injury associated with RIF and INH co-therapy.
We investigated the bile metabolome in hPXR mice to provide mechanistic clues to the hepatotoxicity induced by RIF and INH. Metabolomic analysis revealed two clusters corresponding to the untreated group and the RIF and INH co-treated group (Fig. 2a) , suggesting substantial differences in the chemical components between these two groups. The corresponding S plot shows the ion contribution to this group separation (Fig. 2b) . The highest ranking ion was not RIF or its metabolite but was rather an endogenous chemical, protoporphyrin IX (PPIX) (Fig. 2b) . We confirmed the identity of PPIX by comparing it with an authentic standard ( Supplementary  Fig. 5 ). We found extremely high concentrations of PPIX in the bile of hPXR mice co-treated with RIF and INH but not in the other hPXR groups (controls or treatment with either RIF or INH alone) (Fig. 2c) Co-therapy with rifampicin (RIF) and isoniazid (INH) used to treat tuberculosis in humans frequently causes liver injury. Here, using a pregnane X receptor (PXR)-humanized mouse model, we found that co-treatment with RIF and INH causes accumulation of the endogenous hepatotoxin protoporphyrin IX in the liver through PXR-mediated alteration of the heme biosynthesis pathway. These results provide insight into the mechanism of liver injury induced by co-treatment with these compounds and may lead to their safer use in the clinic.
protoporphyria, a disease of porphyrin metabolism characterized by abnormally elevated concentrations of PPIX in blood and liver. High concentrations of PPIX in the liver are known to cause liver injury 17, 18 . Here we found high concentrations of PPIX in the bile of hPXR mice co-treated with RIF and INH but not in that of WT or Pxr-null mice under the same treatment (Fig. 2d) . These data provide a link between PPIX and the PXRmediated liver injury caused by co-therapy with RIF and INH.
Aminolevulinic acid synthase (ALAS) is the rate-limiting enzyme in porphyrin biosynthesis. Activation of PXR is known to upregulate ALAS1 expression in liver 19 . Because PXR is predominantly expressed in the liver 5, 6 , PXR activation has no effect or a very weak effect on ALAS expression in other organs, including bone marrow. ALA is the product of ALAS1 and is a precursor of PPIX. In hPXR mice co-treated with ALA, RIF and INH, we found more significant liver injury compared to hPXR mice co-treated with RIF and INH only (Fig. 2e,f) . These data illustrate that co-therapy with RIF and INH targets porphyrin biosynthesis and results in hepatic PPIX accumulation and liver injury. These results also explain why RIF and INH are contraindicated in patients with porphyria (http:// www.porphyria.uct.ac.za/professional/prof-tuberculosis.htm). This study offers a new paradigm for understanding the mechanism of liver injury that is associated with RIF and INH co-therapy. New strategies based on human PXR, ALAS and PPIX are expected to predict, prevent and treat liver injury induced by RIF and INH.
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